Nicolas Duployez
Nicolas Duployez
CHU Lille, INSERM U1277, Hematology Department
Verified email at chru-lille.fr - Homepage
Title
Cited by
Cited by
Year
Comprehensive mutational profiling of core binding factor acute myeloid leukemia
N Duployez, A Marceau-Renaut, N Boissel, A Petit, M Bucci, S Geffroy, ...
Blood 127 (20), 2451-2459, 2016
1512016
Frequent ASXL2 mutations in acute myeloid leukemia patients with t (8;21)/RUNX1-RUNX1T1 chromosomal translocations
JB Micol, N Duployez, N Boissel, A Petit, S Geffroy, O Nibourel, ...
Blood 124 (9), 1445, 2014
1072014
Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia
I Antony-Debré, N Duployez, M Bucci, S Geffroy, JB Micol, A Renneville, ...
Leukemia 30 (4), 999-1002, 2016
622016
Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors
N Duployez, C Willekens, A Marceau-Renaut, E Boudry-Labis, ...
Expert review of hematology 8 (1), 43-56, 2015
332015
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia
R Itzykson, N Duployez, A Fasan, G Decool, A Marceau-Renaut, ...
Blood, The Journal of the American Society of Hematology 132 (2), 187-196, 2018
272018
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia
R Itzykson, N Duployez, A Fasan, G Decool, A Marceau-Renaut, ...
Blood, The Journal of the American Society of Hematology 132 (2), 187-196, 2018
272018
Acute myeloid leukemia: the good, the bad, and the ugly
A Kuykendall, N Duployez, N Boissel, JE Lancet, JS Welch
American Society of Clinical Oncology Educational Book 38, 555-573, 2018
272018
ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia
JB Micol, A Pastore, D Inoue, N Duployez, E Kim, SCW Lee, BH Durham, ...
Nature communications 8 (1), 1-13, 2017
272017
Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes
M Meunier, S Ancelet, C Lefebvre, J Arnaud, C Garrel, M Pezet, Y Wang, ...
Oncotarget 8 (62), 105510, 2017
262017
NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors
N Duployez, G Grzych, B Ducourneau, MA Fuentes, N Grardel, T Boyer, ...
Haematologica 101 (4), e133, 2016
262016
Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1‐RUNX1T1 fusion quantification on genomic DNA
N Duployez, O Nibourel, A Marceau‐Renaut, C Willekens, N Helevaut, ...
American journal of hematology 89 (6), 610-615, 2014
252014
Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists
N Duployez, S Lejeune, A Renneville, C Preudhomme
Expert review of hematology 9 (12), 1189-1202, 2016
212016
Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements
I Tanasi, I Ba, N Sirvent, T Braun, W Cuccuini, P Ballerini, N Duployez, ...
Blood, The Journal of the American Society of Hematology 134 (16), 1351-1355, 2019
202019
Multi‐loci diagnosis of acute lymphoblastic leukaemia with high‐throughput sequencing and bioinformatics analysis
Y Ferret, A Caillault, S Sebda, M Duez, N Grardel, N Duployez, C Villenet, ...
British journal of haematology 173 (3), 413-420, 2016
172016
Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t (4; 11)(q21; q23) and cytogenetic evolution under CD19-targeted therapy
E Balducci, V Nivaggioni, J Boudjarane, L Bouriche, I Rahal, D Bernot, ...
Annals of hematology 96 (9), 1579-1581, 2017
162017
Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t (8; 21)
N Duployez, JB Micol, N Boissel, A Petit, S Geffroy, M Bucci, H Lapillonne, ...
Leukemia & lymphoma 57 (1), 199-200, 2016
162016
The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia
N Duployez, A Marceau-Renaut, C Villenet, A Petit, A Rousseau, SWK Ng, ...
Leukemia 33 (2), 348-357, 2019
152019
Molecular profiling defines distinct prognostic subgroups in childhood AML: a report from the French ELAM02 Study Group
A Marceau-Renaut, N Duployez, B Ducourneau, M Labopin, A Petit, ...
HemaSphere 2 (1), 2018
152018
High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones
M Salson, M Giraud, A Caillault, N Grardel, N Duployez, Y Ferret, M Duez, ...
Leukemia research 53, 1-7, 2017
142017
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia
E Fournier, N Duployez, B Ducourneau, E Raffoux, P Turlure, D Caillot, ...
Blood, The Journal of the American Society of Hematology 135 (8), 542-546, 2020
122020
The system can't perform the operation now. Try again later.
Articles 1–20